Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

13.62 +0.21 (+1.60%)
Streaming Delayed Price Updated: 11:40 AM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Amneal (AMRX) Q3 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amneal (AMRX) Q2 2025 Earnings Transcript ↗
Amneal (AMRX) Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Supply Chain
News headline image
1 Value Stock to Target This Week and 2 Facing Challenges
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗
Via Chartmill
Topics Earnings
News headline image
Amneal (AMRX) Q1 2026 Earnings Transcript ↗
Amneal (AMRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know. Amneal ... 
Via StockStory
News headline image
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
From Kashiv BioSciences, LLC
Via Business Wire
News headline image
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ... 
Via StockStory
Topics Economy
News headline image
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
2 Cash-Producing Stocks to Research Further and 1 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 of Wall Street’s Favorite Stocks We Steer Clear Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
Amneal to Report First Quarter 2026 Results on May 1, 2026
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
3 Small-Cap Stocks Walking a Fine Line
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may hav... 
Via StockStory
Topics Stocks
News headline image
3 Value Stocks We’re Skeptical Of
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
Amneal to Participate in Upcoming Investor Conference
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Why Amneal (AMRX) Stock Is Trading Lower Today
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell 6.3% in the afternoon session after the company reported fourth-quarter results that beat expectations but provided a... 
Via StockStory
News headline image
Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 11.5% year on year to $814.3 million. On the other hand,... 
Via StockStory
News headline image
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
News headline image
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates
In a seismic shift for global trade and constitutional law, the Supreme Court of the United States ruled on February 20, 2026, that the executive branch lacks the authority to unilaterally impose... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
3 Russell 2000 Stocks We Find Risky
Via StockStory
News headline image
3 Small-Cap Stocks That Fall Short
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
3 Cash-Producing Stocks That Concern Us
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.